Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 277
Filter
1.
Journal Français d'Ophtalmologie ; 2022.
Article in French | ScienceDirect | ID: covidwho-2041931

ABSTRACT

Résumé La pandémie de Coronavirus Disease 2019 (COVID-19) a émergé à Wuhan, en Chine. Causée par un virus, le SARS-CoV-2, cette dernière s’est répandue dans le monde en quelques semaines. Parallèlement à la gestion de la crise sanitaire sur le terrain, la communauté scientifique s’est penchée sur un moyen de l’enrayer. Des vaccins candidats à ARNm tels que Pfizer BNT162b2 et Moderna m-RNA-1273 ont donc été développés. Leur récente mise sur le marché soulève cependant des inquiétudes quant à leurs potentiels effets secondaires, parmi eux, le zona ophtalmique. Summary Coronavirus disease 19 (COVID-19) was first observed in Wuhan, China. The disease is caused by a virus (SARS-CoV-2), which spread around the world within a matter of weeks, leading to a large number of deaths. While the health crisis was managed on the ground, the scientific community focused on finding a means to stop it. Vaccine candidates such as the mRNA vaccines (Pfizer BTN162b2 and Moderna mRNA-1273), started to emerge. As these treatments came on the market recently, there is still concern about potential side effects, among them, Herpes Zoster Ophthalmicus (HZO).

2.
Respirology Case Reports ; 10(10), 2022.
Article in English | Web of Science | ID: covidwho-2041238

ABSTRACT

IgG4-related disease is characterized by a systemic fibroinflammatory process associated with substantial infiltration by plasma cells with IgG4 in the organs. Our patient presented with pleural effusion, and was diagnosed with IgG4-related lung disease (IgG4-RLD) after he received two doses of the Pfizer COVID-19 vaccine. The patient developed dyspnea and hypoxia 2 weeks after receiving the second dose of the Pfizer COVID-19 vaccine. CT scan revealed left pleural effusion which was drained. However, the effusion recurred requiring thoracoscopic drainage, placement of an indwelling catheter, and decortication with biopsy. IgG4 serum level was 268 mg/dl and pathology revealed pleural fibrosis, lymphoplasmacytic infiltrates, and increased IgG4-positive plasma cells with no malignant cells leading to a diagnosis of IgG4-RLD. Although COVID vaccine-related IgG4-RLD is a novel finding, having a high degree of suspicion following vaccination is always important for early diagnosis and effective treatment.

3.
J Hosp Infect ; 2022.
Article in English | ScienceDirect | ID: covidwho-2031453

ABSTRACT

INTRODUCTION: The role of fomites in the transmission of SARS-CoV-2 is unclear. Our objective was to assess whether SARS-CoV-2 can be transmitted through fomites, using evidence from viral culture studies. METHODS: We conducted searches in the WHO Covid-19 Database, PubMed, LitCovid, medRxiv, and Google Scholar to 31 December 2021. We included studies that investigated fomite transmission and performed viral culture to assess the cytopathic effect (CPE) of positive fomite samples and confirmation of SARS-CoV-2 as the cause of the CPE. We assessed the risk of bias using a checklist modified from the QUADAS-2 criteria. RESULTS: We included 23 studies. The overall risk of bias was moderate. Five studies demonstrated replication-competent virus from fomite cultures and three used genome sequencing to match fomite samples with human clinical specimens. The mean Ct of samples with positive viral culture was significantly lower compared with cultured samples that returned negative results: SMD -1.45, 95%CI -2.00 to -0.90, I(2)=0%;P<0.00001. The likelihood of isolating replication-competent virus was significantly greater when the Ct was <30: RR 3.10 (95%CI 1.32 to 7.31, I(2)=71%, P=0.01). Infectious specimens were mostly detected within 7 days of symptom onset. One study showed possible transmission of SARS-CoV-2 from fomites to humans. CONCLUSION: The evidence from published studies suggests that replication-competent SARS-CoV-2 is present on fomites. Replication-competent SARS-CoV-2 is significantly more likely when the PCR Ct for clinical specimens and fomite samples is <30. Further studies should investigate the duration of infectiousness of SARS-CoV-2 and the frequency of transmission from fomites.

4.
J Clin Virol Plus ; : 100109, 2022.
Article in English | ScienceDirect | ID: covidwho-2031436

ABSTRACT

The Omicron emerged in November 2021 and became the predominant SARS-CoV-2 variant globally. It spreads more rapidly than ancestral lineages and its rapid detection is critical for the prevention of disease outbreaks. Antigen tests such as immunochromatographic assay (ICA) and chemiluminescent enzyme immunoassay (CLEIA) yield results more quickly than standard polymerase chain reaction (PCR). However, their utility for the detection of the Omicron variant remains unclear. We herein evaluated the performance of ICA and CLEIA in saliva from 51 patients with Omicron and 60 PCR negative individuals. The sensitivity and specificity of CLEIA were 98.0% (95%CI: 89.6-100.0%) and 100.0% (95%CI: 94.0-100.0%), respectively, with fine correlation with cycle threshold (Ct) values. The sensitivity and specificity of ICA were 58.8% (95%CI: 44.2-72.4%) and 100.0% (95%CI: 94.0-100.0%), respectively. The sensitivity of ICA was 100.0% (95%CI: 80.5-100.0%) when PCR Ct was less than 25. The Omicron can be efficiently detected in saliva by CLEIA. ICA also detects high viral load Omicron using saliva.

5.
Infect Dis Now ; 2022.
Article in English | ScienceDirect | ID: covidwho-2031323

ABSTRACT

OBJECTIVES: To determine the predictors of a positive SARS-CoV-2 test in a pediatric ambulatory setting. PATIENTS AND METHODS: We performed a cross-sectional prospective study (November 2020-February 2022) of 93 ambulatory settings in France. We included symptomatic children <15 years old tested for COVID-19. For each period corresponding to the spread of the original strain and its variants (period 1: original strain;period 2: Alpha, period 3: Delta;period 4: Omicron), we used a multivariate analysis to estimate adjusted odds ratios (aORs) associated with COVID-19 among age, signs, symptoms or contact, and 95% confidence intervals (95CIs). RESULTS: Of 5,336 children, 13.9% (95CI 13.0-14.8) had a positive test. During the first three periods, the positivity rate ranged from 5.6% (95CI 4.6-6.7) to 12.6% (95CI 10.8-14.6). The main factors associated with a positive test were contact with an infected adult at home or outside the home (aOR 11.5 [95CI 4.9-26.9] to 38.9 [95CI 19.3-78.7]) or an infected household child (aOR 15.0 [95CI 4.8-47.1] to 28.4 [95CI 8.7-92.6]). By contrast, during period 4, aORs for these predictors were substantially lower (2.3 [95CI 1.1-4.5] to 5.5 [95CI 3.2-7.7]), but the positivity rate was 45.7% (95CI 42.3-49.2). CONCLUSIONS: In pediatric ambulatory settings, before the Omicron period, the main predictor of a positive test was contact with an infected person. During the Omicron period, the odds of these predictors were substantially lower while the positivity rate was higher. An accurate diagnostic strategy should only rely on testing and not on age, signs, symptoms or contact.

6.
Heliyon ; : e10583, 2022.
Article in English | ScienceDirect | ID: covidwho-2031297

ABSTRACT

Background: COVID-19 vaccination is one of the pivotal key tools against the ongoing pandemic, but its acceptance relies on efficacy and safety data among various populations, including patients with cancers. However, there is limited data on seroconversion rates, efficacy, and safety of the COVID-19 vaccine in patients with cancer. Breakthrough infections after vaccination have also been reported, which could further strengthen the refusal behavior of specific populations to be immunized. Our objective was to investigate the efficacy and safety of COVID-19 vaccination in real-world patients with advanced genitourinary cancers. Methods and results: A retrospective study of the 738 patients with advanced metastatic genitourinary malignancy was conducted at our genitourinary oncology clinic from October 2020 to September 2021, out of which 462 patients (62.6%) were vaccinated. During the study period, two vaccinated, and six unvaccinated patients tested positive for SARS-CoV-2 (breakthrough infection rate: 0.4% vs. 2.2%, p = 0.027). Vaccine protection against infection was 81.8% (95% CI: 0.04-0.98). One vaccinated and 4 unvaccinated patients were hospitalized due to COVID-19 (0.2% vs. 1.4%, p = 0.048). Vaccine effectiveness in preventing hospitalization was 85.7% (95% CI: 0.02-1.33). Within one month of vaccination, 1.5% of patients (n = 7) had emergency visits, 0.8% (n = 4) were hospitalized for any reason, and of these, 3 (0.6%) experienced a delay in the receipt of their cancer therapy. Conclusion: In our hypothesis-generating data among patients with advanced genitourinary cancers, COVID-19 vaccination was efficacious and safe and was rarely associated with treatment disruptions. These data should help improve the acceptance of the COVID-19 vaccine in the general population and patients with cancer. The vaccine effectiveness in our patients is comparable with existing published data without cancer.

7.
J Clin Pathol ; 2022.
Article in English | Web of Science | ID: covidwho-2020140

ABSTRACT

BACKGROUND: Serological tests are widely used in various medical disciplines for diagnostic and monitoring purposes. Unfortunately, the sensitivity and specificity of test systems are often poor, leaving room for false-positive and false-negative results. However, conventional methods were used to increase specificity and decrease sensitivity and vice versa. Using SARS-CoV-2 serology as an example, we propose here a novel testing strategy: the 'sensitivity improved two-test' or 'SIT(2)' algorithm. METHODS: SIT(2) involves confirmatory retesting of samples with results falling in a predefined retesting zone of an initial screening test, with adjusted cut-offs to increase sensitivity. We verified and compared the performance of SIT(2) to single tests and orthogonal testing (OTA) in an Austrian cohort (1117 negative, 64 post-COVID-positive samples) and validated the algorithm in an independent British cohort (976 negatives and 536 positives). RESULTS: The specificity of SIT(2) was superior to single tests and non-inferior to OTA. The sensitivity was maintained or even improved using SIT(2) when compared with single tests or OTA. SIT(2) allowed correct identification of infected individuals even when a live virus neutralisation assay could not detect antibodies. Compared with single testing or OTA, SIT(2) significantly reduced total test errors to 0.46% (0.24-0.65) or 1.60% (0.94-2.38) at both 5% or 20% seroprevalence. CONCLUSION: For SARS-CoV-2 serology, SIT(2) proved to be the best diagnostic choice at both 5% and 20% seroprevalence in all tested scenarios. It is an easy to apply algorithm and can potentially be helpful for the serology of other infectious diseases.

8.
Clin Infect Dis ; 2022 Feb 09.
Article in English | MEDLINE | ID: covidwho-2017830

ABSTRACT

BACKGROUND: Persons on chronic hemodialysis have a significantly diminished humoral immune response to SARS-CoV-2 vaccines. Whether this translates to reduced vaccine effectiveness (VE) is unknown. METHODS: We used the US Department of Veterans Affairs COVID-19 Shared Data Resource to identify all Veterans who were tested for SARS-CoV-2 between January 26, 2021 and August 31, 2021. Using International Classification of Diseases, 10 th edition codes and attendance at a dialysis clinic or center, we identified those who were on chronic hemodialysis. We used a test-negative, case-control design using a doubly-robust logistic regression model to determine the VE of the BNT-162b2 (Pfizer) or mRNA-1273 (Moderna) vaccines in preventing confirmed SARS-CoV-2 infection. RESULTS: Among 847,199 Veterans tested for SARS-CoV-2 between January 26, 2021 and August 31, 2021, there were 6,076 Veterans on chronic hemodialysis. Among those, we identified 1,270 cases (580 fully vaccinated) and 2,959 controls (2,120 fully vaccinated). The overall VE >14 days after the second dose in preventing documented infection was 68.2% (95% CI:62.6,72.9). VE was 68.9% (95% CI:61.9,74.7) for Pfizer-BNT-162b2 and 66.7% (95% CI:58.9,73.0) for Moderna-mRNA-1273 vaccine. There was no difference in VE by age (<70 vs. >70 years), race or sex. There were no events recorded in persons with a Charlson's comorbidity index score of <2. CONCLUSION: VE of two doses of current mRNA vaccines in preventing SARS-CoV-2 infection in persons on chronic hemodialysis is lower than historic VE rates in the general population. Effect of additional doses in improving VE in this special population needs further study.

9.
Science ; 377(6610):1025-1025, 2022.
Article in English | Academic Search Complete | ID: covidwho-2010693

ABSTRACT

The article reports on the accusation made by Moderna on its rival Pfizer and its partner BioNTech of infringing the company's patents for a similar mRNA shot.

11.
Vaccine ; 2022.
Article in English | ScienceDirect | ID: covidwho-2004584

ABSTRACT

Introduction In 2020, prior to COVID-19 vaccine rollout, the Brighton Collaboration created a priority list, endorsed by the World Health Organization, of potential adverse events relevant to COVID-19 vaccines. We adapted the Brighton Collaboration list to evaluate serious adverse events of special interest observed in mRNA COVID-19 vaccine trials. Methods Secondary analysis of serious adverse events reported in the placebo-controlled, phase III randomized clinical trials of Pfizer and Moderna mRNA COVID-19 vaccines in adults (NCT04368728 and NCT04470427), focusing analysis on Brighton Collaboration adverse events of special interest. Results Pfizer and Moderna mRNA COVID-19 vaccines were associated with an excess risk of serious adverse events of special interest of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95 % CI −0.4 to 20.6 and −3.6 to 33.8), respectively. Combined, the mRNA vaccines were associated with an excess risk of serious adverse events of special interest of 12.5 per 10,000 vaccinated (95 % CI 2.1 to 22.9);risk ratio 1.43 (95 % CI 1.07 to 1.92). The Pfizer trial exhibited a 36 % higher risk of serious adverse events in the vaccine group;risk difference 18.0 per 10,000 vaccinated (95 % CI 1.2 to 34.9);risk ratio 1.36 (95 % CI 1.02 to 1.83). The Moderna trial exhibited a 6 % higher risk of serious adverse events in the vaccine group: risk difference 7.1 per 10,000 (95 % CI –23.2 to 37.4);risk ratio 1.06 (95 % CI 0.84 to 1.33). Combined, there was a 16 % higher risk of serious adverse events in mRNA vaccine recipients: risk difference 13.2 (95 % CI −3.2 to 29.6);risk ratio 1.16 (95 % CI 0.97 to 1.39). Discussion The excess risk of serious adverse events found in our study points to the need for formal harm-benefit analyses, particularly those that are stratified according to risk of serious COVID-19 outcomes. These analyses will require public release of participant level datasets.

12.
Lancet Reg Health Eur ; 19: 100429, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-2004324

ABSTRACT

Background: We aimed to explore the effectiveness of one-dose BNT162b2 vaccination upon SARS-CoV-2 infection, its effect on COVID-19 presentation, and post-vaccination symptoms in children and adolescents (CA) in the UK during periods of Delta and Omicron variant predominance. Methods: In this prospective longitudinal cohort study, we analysed data from 115,775 CA aged 12-17 years, proxy-reported through the Covid Symptom Study (CSS) smartphone application. We calculated post-vaccination infection risk after one dose of BNT162b2, and described the illness profile of CA with post-vaccination SARS-CoV-2 infection, compared to unvaccinated CA, and post-vaccination side-effects. Findings: Between August 5, 2021 and February 14, 2022, 25,971 UK CA aged 12-17 years received one dose of BNT162b2 vaccine. The probability of testing positive for infection diverged soon after vaccination, and was lower in CA with prior SARS-CoV-2 infection. Vaccination reduced proxy-reported infection risk (-80·4% (95% CI -0·82 -0·78) and -53·7% (95% CI -0·62 -0·43) at 14-30 days with Delta and Omicron variants respectively, and -61·5% (95% CI -0·74 -0·44) and -63·7% (95% CI -0·68 -0.59) after 61-90 days). Vaccinated CA who contracted SARS-CoV-2 during the Delta period had milder disease than unvaccinated CA; during the Omicron period this was only evident in children aged 12-15 years. Overall disease profile was similar in both vaccinated and unvaccinated CA. Post-vaccination local side-effects were common, systemic side-effects were uncommon, and both resolved within few days (3 days in most cases). Interpretation: One dose of BNT162b2 vaccine reduced risk of SARS-CoV-2 infection for at least 90 days in CA aged 12-17 years. Vaccine protection varied for SARS-CoV-2 variant type (lower for Omicron than Delta variant), and was enhanced by pre-vaccination SARS-CoV-2 infection. Severity of COVID-19 presentation after vaccination was generally milder, although unvaccinated CA also had generally mild disease. Overall, vaccination was well-tolerated. Funding: UK Government Department of Health and Social Care, Chronic Disease Research Foundation, The Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare, UK National Institute for Health Research, UK Medical Research Council, British Heart Foundation and Alzheimer's Society, and ZOE Limited.

13.
Proceedings of the International Scientific Conference Economic and Social Policy ; : 381-394, 2021.
Article in English | Web of Science | ID: covidwho-2003355

ABSTRACT

Now, the pharma sector is strong performer in the world economy, according to global data. In the introduction, I present a view of the global pandemic of covid-19 and its impact on health in the Slovak economy compared to another country. Article gives an overview of the significant pharma industry as an important and growing sector for many economies. The primary goal is to present vaccination developing that has saved an untold number of lives. The partial objectives of the paper to ask whether it is right for big drug companies to effectively profit from the pandemic, or to sell vaccines on a non-profit basis. Rich countries must open the way to cheaper mass-produced covid-19 vaccines to protect every person in the world and to prevent global economic catastrophe.

14.
Reprod Sci ; 2022.
Article in English | PubMed | ID: covidwho-2000190

ABSTRACT

The objective of this research was to characterize menstrual changes including amount, duration, and frequency among COVID-19 vaccinated and infected women. We conducted an online nationwide questionnaire survey on premenopausal, non-pregnant women over 18 years of age in Israel, querying about any changes in their menstrual patterns after COVID-19 vaccination or infection. In total, 10,319 women responded, of which 7904 met the inclusion criteria. Changes in menstrual patterns following COVID-19 vaccination or infection were reported in 3689/7476 (49.3%) women compared with 202/428 (47.2%) women, respectively, (P = .387). The most commonly described menstrual disturbance was excessive bleeding (heavy, prolonged, or intermenstrual) in both the vaccinated and infected groups, (80.6% versus 81.4%, respectively, P = .720). Among women who experienced abnormal uterine bleeding (AUB), in most cases (61.1%), it occurred between the vaccination and the ensuing menstrual period. Menstrual disturbances were similar in type among the vaccinated and infected women. In conclusion, AUB emerged as a side effect of the BNT162b2 vaccine and a symptom of the COVID-19 infection and was characterized mainly by excessive bleeding. Although the precise incidence could not be determined in this study, the type of bleeding disorder as well as the characterization of risk factors including increasing age and a baseline menstrual pattern of prolonged, frequent, and heavy menses are well defined. The incidence and the long-term consequences of the BNT162b2 vaccine on uterine bleeding warrant further investigation.

15.
Cureus Journal of Medical Science ; 14(7), 2022.
Article in English | Web of Science | ID: covidwho-1998012

ABSTRACT

Pityriasis rosea (PR) is an acute self-limiting exanthematous skin disorder characterized by the presence of a primary solitary lesion called a herald patch and the subsequent development of diffuse papulosquamous lesions within 1 to 2 weeks. This is a case of COVID-19 vaccine-induced PR in the age group (12-18 years) that was recently approved for vaccination. We report a case of a 15-year-old otherwise healthy female with a history of 2 weeks of single oval primary plaque appearing on the right wrist 2 days after receiving the second dose of Pfizer-BioNTech vaccine, followed by diffuse and mild itchy skin eruptions spreading over the abdomen, back, chest, and extremities. The patient had no other symptoms and no PR risk factors. The patient was placed on 800 mg acyclovir five times a day and improved markedly after 1 week. As vaccine -induced PR/PR-like eruptions (PR-LE) is an uncommon phenomenon, we recommend further studies to determine the association between PR/PR-LE and COVID-19 vaccination.

16.
Alexandria Engineering Journal ; 61(12):12091-12110, 2022.
Article in English | Web of Science | ID: covidwho-1995938

ABSTRACT

Recent studies regarding COVID-19 show a growing tendency to talk about the COVID-19 Pandemic on online channels. With the recent release of the Pfizer vaccine of COVID-19, people keep posting many rumors regarding the safety concerns of the Vaccine, especially among older people. Due to the rapid spread of the COVID-19 virus and the worldwide Pandemic developed, the rush to develop the COVID-19 Vaccine has become an alarming priority in health care services worldwide. In this research work, we have systematically evaluated people's views towards the COVID-19 Vaccine, and shreds of evidence are supported empirically. The study mainly focuses on the empirical evidence and intensive discussions on what is currently known about the mechanism of action, efficacy, and toxicity of the most promising vaccines (Moderna), (Pfizer/BioNtech), (Astrazenac/Oxford), and (Sputnik V) against COVID-19. Our study's primary objective is to provide an analysis of the questionnaire regarding people's opinions, preferences, and acceptance of the COVID-19 vaccines. We have created an online questionnaire using a google form to collect data from various countries supposed to employ COVID-19 vaccines. The questionnaires were distributed to people in many Arab and foreign countries such as Egypt, Saudi Arabia, India, England, China, and Japan. A total of 516 responses were returned and analyzed using statistical, and Seasonal Autoregressive Integrated Moving Average (SARIMA) approaches. The SARIMA model is used to predict the total number of vaccines in the next few days. To attain the most accurate forecast and prediction, the SARIMA model parameters are investigated with a grid search method. Finally, the combination of the parameters (1, 0, 1) x (1, 0, 0, 1) is considered to be the best SAR-IMA model because it has the lowest AIC values of - 4100.11 and the best Correlation coefficients of 0.984. (C) 2022 THE AUTHORS. Published by Elsevier BV on behalf of Faculty of Engineering, Alexandria University This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

17.
J Virol ; : e0058222, 2022 Aug 17.
Article in English | MEDLINE | ID: covidwho-1992936

ABSTRACT

Emerging variants, especially the recent Omicron variant, and gaps in vaccine coverage threaten mRNA vaccine mediated protection against SARS-CoV-2. While children have been relatively spared by the ongoing pandemic, increasing case numbers and hospitalizations are now evident among children. Thus, it is essential to better understand the magnitude and breadth of vaccine-induced immunity in children against circulating viral variant of concerns (VOCs). Here, we compared the magnitude and breadth of humoral immune responses in adolescents and adults 1 month after the two-dose Pfizer (BNT162b2) vaccination. We found that adolescents (aged 11 to 16) demonstrated more robust binding antibody and neutralization responses against the wild-type SARS-CoV-2 virus spike protein contained in the vaccine compared to adults (aged 27 to 55). The quality of the antibody responses against VOCs in adolescents were very similar to adults, with modest changes in binding and neutralization of Beta, Gamma, and Delta variants. In comparison, a significant reduction of binding titers and a striking lack of neutralization was observed against the newly emerging Omicron variant for both adolescents and adults. Overall, our data show that a two-dose BNT162b2 vaccine series may be insufficient to protect against the Omicron variant. IMPORTANCE While plasma binding and neutralizing antibody responses have been reported for cohorts of infected and vaccinated adults, much less is known about the vaccine-induced antibody responses to variants including Omicron in children. This illustrates the need to characterize vaccine efficacy in key vulnerable populations. A third (booster) dose of BNTb162b was approved for children 12 to 15 years of age by the Food and Drug Administration (FDA) on January 1, 2022, and pediatric clinical trials are under way to evaluate the safety, immunogenicity, and effectiveness of a third dose in younger children. Similarly, variant-specific booster doses and pan-coronavirus vaccines are areas of active research. Our data show adolescents mounted stronger humoral immune responses after vaccination than adults. It also highlights the need for future studies of antibody durability in adolescents and children as well as the need for future studies of booster vaccination and their efficacy against the Omicron variant.

18.
Dermatol Ther ; : e15769, 2022 Aug 12.
Article in English | MEDLINE | ID: covidwho-1992772
19.
J Neuroimmunol ; 368: 577883, 2022 07 15.
Article in English | MEDLINE | ID: covidwho-1991160

ABSTRACT

INTRODUCTION: Large-scale vaccination is considered one of the most effective strategies to control the pandemic of COVID-19. Since its start, different complications have been described thought to be related to vaccination. Here, we present a rare case where encephalopathy, myocarditis, and thrombocytopenia developed simultaneously following the second dose of Pfizer-BioNTech mRNA vaccine (BNT162b2). CASE PRESENTATION: A 15-years-old female presented with fever, altered consciousness, and convulsions after taking the second shot of the vaccine. Clinical and laboratory workup was notable for the presence of thrombocytopenia and myocarditis. No alternative causes of encephalitis were found. The patient responded significantly to methylprednisolone suggesting underlying immune pathogenesis responsible for the clinical features. The diagnostic criteria for possible autoimmune encephalitis were also fulfilled. CONCLUSION: Although rare, the clinician should be aware of the possible adverse events following COVID-19 vaccination. Further research with large pooled data is needed to get more insight into its pathogenesis and causal relationship.


Subject(s)
Brain Diseases , COVID-19 , Encephalitis , Myocarditis , Thrombocytopenia , Adolescent , BNT162 Vaccine , COVID-19 Vaccines/adverse effects , Encephalitis/complications , Female , Humans , Methylprednisolone/therapeutic use , Myocarditis/diagnosis , Myocarditis/etiology , Thrombocytopenia/chemically induced , Vaccines, Synthetic , mRNA Vaccines
20.
Cir Cir ; 90(3): 410-413, 2022.
Article in English | MEDLINE | ID: covidwho-1988867

ABSTRACT

The differential diagnosis of the metastatic axillary lymphadenopathies of breast cancer with which they occur secondary to the Pfizer-BioNTech vaccine against COVID-19, is imperative. In a series of cases, we analyzed the characteristics of unilateral axillary lymphadenopathy in patients after Pfizer-BioNTech vaccination. Axillary lymphadenopathy were observed ipsilateral to the vaccination arm. The axillary ultrasound defined these as reactive and that they disappeared in 3 weeks. The pathological findings were benign. The anamnesis, the place and date of vaccination and the radiological findings, play an essential role to carry out a correct differential diagnosis and follow-up of these adenopathies.


El diagnóstico diferencial de las adenopatías axilares metastásicas del cáncer de mama con las que se producen secundarias a la vacuna de Pfizer-BioNTech contra la COVID-19 es imperioso. Analizamos una serie de casos con las características de las adenopatías axilares unilaterales tras la administración de la vacuna de Pfizer-BioNTech. Se observaron adenopatías axilares homolaterales al brazo de vacunación. La ecografía axilar las definió como reactivas y que desaparecían en 3 semanas. Los hallazgos anatomopatológicos fueron de benignidad. La anamnesis, el lugar y la fecha de vacunación, así como los hallazgos radiológicos, desempeñan un papel esencial para realizar un correcto diagnóstico deferencial y el seguimiento de estas adenopatías.


Subject(s)
Breast Neoplasms , COVID-19 , Lymphadenopathy , Breast Neoplasms/pathology , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Female , Humans , Lymphadenopathy/etiology , Lymphatic Metastasis , SARS-CoV-2 , Vaccination
SELECTION OF CITATIONS
SEARCH DETAIL